nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—BRAF—bone cancer	0.298	0.494	CbGaD
Nilotinib—KIT—bone cancer	0.24	0.396	CbGaD
Nilotinib—CYP3A4—bone cancer	0.0663	0.11	CbGaD
Nilotinib—ABCG2—Carboplatin—bone cancer	0.0221	0.187	CbGbCtD
Nilotinib—ABCG2—Cisplatin—bone cancer	0.0188	0.16	CbGbCtD
Nilotinib—CYP2B6—Cisplatin—bone cancer	0.0133	0.113	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—bone cancer	0.0126	0.107	CbGbCtD
Nilotinib—ABCG2—Methotrexate—bone cancer	0.0122	0.104	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—bone cancer	0.00888	0.0755	CbGbCtD
Nilotinib—CYP2C9—Cisplatin—bone cancer	0.007	0.0595	CbGbCtD
Nilotinib—ABCB1—Cisplatin—bone cancer	0.0068	0.0578	CbGbCtD
Nilotinib—MAPK8—periosteum—bone cancer	0.00469	0.129	CbGeAlD
Nilotinib—ABCB1—Doxorubicin—bone cancer	0.00455	0.0387	CbGbCtD
Nilotinib—ABCB1—Methotrexate—bone cancer	0.00441	0.0375	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—bone cancer	0.00429	0.0365	CbGbCtD
Nilotinib—MAPK8—cartilage tissue—bone cancer	0.00329	0.0906	CbGeAlD
Nilotinib—CYP3A4—Doxorubicin—bone cancer	0.00273	0.0232	CbGbCtD
Nilotinib—Ponatinib—KIT—bone cancer	0.00217	0.485	CrCbGaD
Nilotinib—CSF1R—periosteum—bone cancer	0.00216	0.0594	CbGeAlD
Nilotinib—Imatinib—KIT—bone cancer	0.00134	0.298	CrCbGaD
Nilotinib—CA2—periosteum—bone cancer	0.00116	0.032	CbGeAlD
Nilotinib—MAPK8—connective tissue—bone cancer	0.000818	0.0225	CbGeAlD
Nilotinib—LYN—connective tissue—bone cancer	0.000755	0.0208	CbGeAlD
Nilotinib—CDC42BPB—tendon—bone cancer	0.000622	0.0171	CbGeAlD
Nilotinib—Ponatinib—CYP3A4—bone cancer	0.000602	0.134	CrCbGaD
Nilotinib—CDC42BPB—spinal cord—bone cancer	0.0006	0.0165	CbGeAlD
Nilotinib—MAPK8—tendon—bone cancer	0.000562	0.0155	CbGeAlD
Nilotinib—CA3—connective tissue—bone cancer	0.000557	0.0153	CbGeAlD
Nilotinib—MAPK8—bone marrow—bone cancer	0.000545	0.015	CbGeAlD
Nilotinib—MAPK8—spinal cord—bone cancer	0.000542	0.0149	CbGeAlD
Nilotinib—MAPK14—connective tissue—bone cancer	0.00052	0.0143	CbGeAlD
Nilotinib—MAP4K1—tendon—bone cancer	0.000511	0.0141	CbGeAlD
Nilotinib—MAP4K1—bone marrow—bone cancer	0.000495	0.0136	CbGeAlD
Nilotinib—EPHB4—connective tissue—bone cancer	0.000493	0.0136	CbGeAlD
Nilotinib—TEK—connective tissue—bone cancer	0.000471	0.013	CbGeAlD
Nilotinib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000468	0.173	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000468	0.173	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000468	0.173	CbGdCrCtD
Nilotinib—BRAF—tendon—bone cancer	0.000468	0.0129	CbGeAlD
Nilotinib—BRAF—bone marrow—bone cancer	0.000453	0.0125	CbGeAlD
Nilotinib—EPHB3—spinal cord—bone cancer	0.000447	0.0123	CbGeAlD
Nilotinib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000433	0.16	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000433	0.16	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000433	0.16	CbGdCrCtD
Nilotinib—PDGFRA—connective tissue—bone cancer	0.000427	0.0118	CbGeAlD
Nilotinib—HCK—tendon—bone cancer	0.000426	0.0117	CbGeAlD
Nilotinib—ABL2—tendon—bone cancer	0.000424	0.0117	CbGeAlD
Nilotinib—HCK—bone marrow—bone cancer	0.000413	0.0114	CbGeAlD
Nilotinib—HCK—spinal cord—bone cancer	0.000411	0.0113	CbGeAlD
Nilotinib—CA12—connective tissue—bone cancer	0.000394	0.0109	CbGeAlD
Nilotinib—EPHA4—tendon—bone cancer	0.000387	0.0107	CbGeAlD
Nilotinib—CA3—tendon—bone cancer	0.000383	0.0105	CbGeAlD
Nilotinib—CSF1R—connective tissue—bone cancer	0.000376	0.0104	CbGeAlD
Nilotinib—CA3—bone marrow—bone cancer	0.000371	0.0102	CbGeAlD
Nilotinib—Imatinib—CYP3A4—bone cancer	0.000371	0.0826	CrCbGaD
Nilotinib—CA9—tendon—bone cancer	0.000366	0.0101	CbGeAlD
Nilotinib—MAPK14—tendon—bone cancer	0.000357	0.00983	CbGeAlD
Nilotinib—FGR—tendon—bone cancer	0.000356	0.00979	CbGeAlD
Nilotinib—CA14—tendon—bone cancer	0.000347	0.00957	CbGeAlD
Nilotinib—MAPK14—bone marrow—bone cancer	0.000346	0.00953	CbGeAlD
Nilotinib—FGR—bone marrow—bone cancer	0.000345	0.00949	CbGeAlD
Nilotinib—LCK—bone marrow—bone cancer	0.000345	0.00949	CbGeAlD
Nilotinib—MAPK14—spinal cord—bone cancer	0.000344	0.00948	CbGeAlD
Nilotinib—KIT—connective tissue—bone cancer	0.000341	0.0094	CbGeAlD
Nilotinib—EPHB4—tendon—bone cancer	0.000339	0.00932	CbGeAlD
Nilotinib—CA14—spinal cord—bone cancer	0.000335	0.00923	CbGeAlD
Nilotinib—PDGFRB—connective tissue—bone cancer	0.000333	0.00918	CbGeAlD
Nilotinib—EPHA2—tendon—bone cancer	0.000332	0.00914	CbGeAlD
Nilotinib—EPHB4—bone marrow—bone cancer	0.000328	0.00903	CbGeAlD
Nilotinib—EPHB4—spinal cord—bone cancer	0.000327	0.00899	CbGeAlD
Nilotinib—TEK—tendon—bone cancer	0.000324	0.00892	CbGeAlD
Nilotinib—TEK—spinal cord—bone cancer	0.000313	0.0086	CbGeAlD
Nilotinib—EPHB6—tendon—bone cancer	0.00031	0.00853	CbGeAlD
Nilotinib—EPHB6—spinal cord—bone cancer	0.000299	0.00822	CbGeAlD
Nilotinib—ABL1—connective tissue—bone cancer	0.000297	0.00818	CbGeAlD
Nilotinib—PDGFRA—tendon—bone cancer	0.000294	0.00808	CbGeAlD
Nilotinib—PDGFRA—spinal cord—bone cancer	0.000283	0.0078	CbGeAlD
Nilotinib—MAP2K5—tendon—bone cancer	0.000265	0.00729	CbGeAlD
Nilotinib—CSF1R—tendon—bone cancer	0.000258	0.00712	CbGeAlD
Nilotinib—MAP2K5—spinal cord—bone cancer	0.000255	0.00703	CbGeAlD
Nilotinib—CSF1R—bone marrow—bone cancer	0.00025	0.00689	CbGeAlD
Nilotinib—CSF1R—spinal cord—bone cancer	0.000249	0.00686	CbGeAlD
Nilotinib—PDGFRB—tendon—bone cancer	0.000229	0.00631	CbGeAlD
Nilotinib—KIT—bone marrow—bone cancer	0.000227	0.00626	CbGeAlD
Nilotinib—KIT—spinal cord—bone cancer	0.000226	0.00623	CbGeAlD
Nilotinib—PDGFRB—bone marrow—bone cancer	0.000222	0.00611	CbGeAlD
Nilotinib—PDGFRB—spinal cord—bone cancer	0.000221	0.00609	CbGeAlD
Nilotinib—CA1—bone marrow—bone cancer	0.000208	0.00572	CbGeAlD
Nilotinib—CA1—spinal cord—bone cancer	0.000207	0.0057	CbGeAlD
Nilotinib—ABL1—tendon—bone cancer	0.000204	0.00562	CbGeAlD
Nilotinib—CA2—connective tissue—bone cancer	0.000202	0.00557	CbGeAlD
Nilotinib—ABL1—bone marrow—bone cancer	0.000198	0.00545	CbGeAlD
Nilotinib—ABL1—spinal cord—bone cancer	0.000197	0.00543	CbGeAlD
Nilotinib—CA4—tendon—bone cancer	0.000168	0.00462	CbGeAlD
Nilotinib—CA4—bone marrow—bone cancer	0.000163	0.00447	CbGeAlD
Nilotinib—CA4—spinal cord—bone cancer	0.000162	0.00446	CbGeAlD
Nilotinib—CA2—tendon—bone cancer	0.000139	0.00383	CbGeAlD
Nilotinib—CA2—bone marrow—bone cancer	0.000135	0.00371	CbGeAlD
Nilotinib—CA2—spinal cord—bone cancer	0.000134	0.00369	CbGeAlD
Nilotinib—ABCG2—bone marrow—bone cancer	0.000125	0.00344	CbGeAlD
Nilotinib—ABCG2—spinal cord—bone cancer	0.000124	0.00342	CbGeAlD
Nilotinib—Epistaxis—Epirubicin—bone cancer	0.0001	0.000938	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—bone cancer	0.0001	0.000936	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—bone cancer	0.0001	0.000934	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—bone cancer	9.97e-05	0.000931	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—bone cancer	9.91e-05	0.000926	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—bone cancer	9.86e-05	0.000921	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—bone cancer	9.86e-05	0.000921	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—bone cancer	9.85e-05	0.00092	CcSEcCtD
Nilotinib—Hypersensitivity—Cisplatin—bone cancer	9.75e-05	0.00091	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—bone cancer	9.73e-05	0.000909	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—bone cancer	9.69e-05	0.000905	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—bone cancer	9.66e-05	0.000902	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—bone cancer	9.66e-05	0.000902	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—bone cancer	9.61e-05	0.000898	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—bone cancer	9.61e-05	0.000897	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—bone cancer	9.61e-05	0.000897	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—bone cancer	9.59e-05	0.000895	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—bone cancer	9.58e-05	0.000895	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—bone cancer	9.58e-05	0.000895	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—bone cancer	9.56e-05	0.000893	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—bone cancer	9.56e-05	0.000893	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—bone cancer	9.55e-05	0.000892	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—bone cancer	9.53e-05	0.00089	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—bone cancer	9.51e-05	0.000889	CcSEcCtD
Nilotinib—Asthenia—Cisplatin—bone cancer	9.49e-05	0.000887	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—bone cancer	9.49e-05	0.000886	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—bone cancer	9.48e-05	0.000886	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—bone cancer	9.44e-05	0.000882	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—bone cancer	9.42e-05	0.00088	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—bone cancer	9.4e-05	0.000878	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—bone cancer	9.4e-05	0.000878	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—bone cancer	9.37e-05	0.000875	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—bone cancer	9.32e-05	0.000871	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—bone cancer	9.3e-05	0.000868	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—bone cancer	9.27e-05	0.000866	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—bone cancer	9.23e-05	0.000862	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—bone cancer	9.21e-05	0.000861	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—bone cancer	9.21e-05	0.00086	CcSEcCtD
Nilotinib—Chills—Methotrexate—bone cancer	9.17e-05	0.000856	CcSEcCtD
Nilotinib—Diarrhoea—Cisplatin—bone cancer	9.05e-05	0.000845	CcSEcCtD
Nilotinib—Erythema multiforme—Epirubicin—bone cancer	9.04e-05	0.000844	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—bone cancer	9.03e-05	0.000843	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—bone cancer	9.01e-05	0.000841	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—bone cancer	8.95e-05	0.000836	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—bone cancer	8.94e-05	0.000835	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—bone cancer	8.92e-05	0.000833	CcSEcCtD
Nilotinib—Erythema—Methotrexate—bone cancer	8.89e-05	0.000831	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—bone cancer	8.89e-05	0.000831	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—bone cancer	8.89e-05	0.000831	CcSEcCtD
Nilotinib—Flushing—Epirubicin—bone cancer	8.87e-05	0.000829	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—bone cancer	8.87e-05	0.000829	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—bone cancer	8.87e-05	0.000828	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—bone cancer	8.85e-05	0.000826	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—bone cancer	8.85e-05	0.000826	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—bone cancer	8.8e-05	0.000822	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—bone cancer	8.78e-05	0.00082	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—bone cancer	8.74e-05	0.000816	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—bone cancer	8.72e-05	0.000814	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—bone cancer	8.71e-05	0.000814	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—bone cancer	8.69e-05	0.000812	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—bone cancer	8.68e-05	0.00081	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—bone cancer	8.67e-05	0.00081	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—bone cancer	8.64e-05	0.000807	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—bone cancer	8.62e-05	0.000805	CcSEcCtD
Nilotinib—Back pain—Methotrexate—bone cancer	8.6e-05	0.000804	CcSEcCtD
Nilotinib—Chills—Epirubicin—bone cancer	8.58e-05	0.000801	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—bone cancer	8.54e-05	0.000798	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—bone cancer	8.53e-05	0.000796	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—bone cancer	8.45e-05	0.000789	CcSEcCtD
Nilotinib—Vomiting—Cisplatin—bone cancer	8.41e-05	0.000786	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—bone cancer	8.38e-05	0.000783	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—bone cancer	8.38e-05	0.000782	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—bone cancer	8.37e-05	0.000781	CcSEcCtD
Nilotinib—Rash—Cisplatin—bone cancer	8.34e-05	0.000779	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—bone cancer	8.33e-05	0.000778	CcSEcCtD
Nilotinib—Erythema—Epirubicin—bone cancer	8.32e-05	0.000777	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—bone cancer	8.32e-05	0.000777	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—bone cancer	8.27e-05	0.000772	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—bone cancer	8.25e-05	0.000771	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—bone cancer	8.25e-05	0.00077	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—bone cancer	8.22e-05	0.000768	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—bone cancer	8.21e-05	0.000767	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—bone cancer	8.21e-05	0.000767	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—bone cancer	8.2e-05	0.000766	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—bone cancer	8.15e-05	0.000761	CcSEcCtD
Nilotinib—Back pain—Epirubicin—bone cancer	8.05e-05	0.000752	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—bone cancer	8.03e-05	0.00075	CcSEcCtD
Nilotinib—Malaise—Methotrexate—bone cancer	8.02e-05	0.000749	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—bone cancer	8e-05	0.000747	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—bone cancer	7.99e-05	0.000746	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—bone cancer	7.99e-05	0.000746	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—bone cancer	7.97e-05	0.000745	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—bone cancer	7.96e-05	0.000744	CcSEcCtD
Nilotinib—Chills—Doxorubicin—bone cancer	7.94e-05	0.000741	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—bone cancer	7.9e-05	0.000738	CcSEcCtD
Nilotinib—Nausea—Cisplatin—bone cancer	7.86e-05	0.000734	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—bone cancer	7.84e-05	0.000733	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—bone cancer	7.82e-05	0.00073	CcSEcCtD
Nilotinib—Cough—Methotrexate—bone cancer	7.76e-05	0.000725	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—bone cancer	7.75e-05	0.000724	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—bone cancer	7.72e-05	0.000721	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—bone cancer	7.7e-05	0.000719	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—bone cancer	7.7e-05	0.000719	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—bone cancer	7.69e-05	0.000719	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—bone cancer	7.59e-05	0.000709	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—bone cancer	7.57e-05	0.000707	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—bone cancer	7.57e-05	0.000707	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—bone cancer	7.57e-05	0.000707	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—bone cancer	7.54e-05	0.000704	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.52e-05	0.000702	CcSEcCtD
Nilotinib—Malaise—Epirubicin—bone cancer	7.51e-05	0.000701	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—bone cancer	7.48e-05	0.000699	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—bone cancer	7.48e-05	0.000699	CcSEcCtD
Nilotinib—Syncope—Epirubicin—bone cancer	7.46e-05	0.000697	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—bone cancer	7.45e-05	0.000696	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—bone cancer	7.45e-05	0.000696	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—bone cancer	7.4e-05	0.000692	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—bone cancer	7.36e-05	0.000687	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—bone cancer	7.32e-05	0.000684	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—bone cancer	7.32e-05	0.000683	CcSEcCtD
Nilotinib—Cough—Epirubicin—bone cancer	7.26e-05	0.000678	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—bone cancer	7.26e-05	0.000678	CcSEcCtD
Nilotinib—Infection—Methotrexate—bone cancer	7.21e-05	0.000674	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—bone cancer	7.19e-05	0.000671	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—bone cancer	7.15e-05	0.000667	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—bone cancer	7.12e-05	0.000665	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—bone cancer	7.12e-05	0.000665	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—bone cancer	7.11e-05	0.000664	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—bone cancer	7.09e-05	0.000662	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—bone cancer	7.09e-05	0.000662	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—bone cancer	7.09e-05	0.000662	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—bone cancer	7.06e-05	0.00066	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—bone cancer	7.05e-05	0.000659	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	7.04e-05	0.000657	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—bone cancer	7.02e-05	0.000655	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—bone cancer	7e-05	0.000654	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—bone cancer	6.95e-05	0.000649	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—bone cancer	6.93e-05	0.000647	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—bone cancer	6.92e-05	0.000646	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—bone cancer	6.92e-05	0.000646	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—bone cancer	6.91e-05	0.000645	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—bone cancer	6.89e-05	0.000644	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—bone cancer	6.85e-05	0.00064	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—bone cancer	6.81e-05	0.000636	CcSEcCtD
Nilotinib—Oedema—Epirubicin—bone cancer	6.79e-05	0.000635	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—bone cancer	6.78e-05	0.000634	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—bone cancer	6.77e-05	0.000632	CcSEcCtD
Nilotinib—Infection—Epirubicin—bone cancer	6.75e-05	0.00063	CcSEcCtD
Nilotinib—Cough—Doxorubicin—bone cancer	6.72e-05	0.000628	CcSEcCtD
Nilotinib—Shock—Epirubicin—bone cancer	6.68e-05	0.000624	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—bone cancer	6.66e-05	0.000622	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—bone cancer	6.65e-05	0.000621	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—bone cancer	6.65e-05	0.000621	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—bone cancer	6.63e-05	0.000619	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—bone cancer	6.61e-05	0.000618	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—bone cancer	6.6e-05	0.000616	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—bone cancer	6.57e-05	0.000613	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—bone cancer	6.57e-05	0.000613	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—bone cancer	6.56e-05	0.000612	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—bone cancer	6.56e-05	0.000612	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—bone cancer	6.56e-05	0.000612	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—bone cancer	6.53e-05	0.00061	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—bone cancer	6.52e-05	0.000609	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.51e-05	0.000608	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—bone cancer	6.48e-05	0.000605	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—bone cancer	6.48e-05	0.000605	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—bone cancer	6.47e-05	0.000604	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—bone cancer	6.41e-05	0.000599	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—bone cancer	6.39e-05	0.000597	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—bone cancer	6.35e-05	0.000593	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—bone cancer	6.34e-05	0.000592	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—bone cancer	6.31e-05	0.000589	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—bone cancer	6.29e-05	0.000587	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—bone cancer	6.27e-05	0.000585	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—bone cancer	6.26e-05	0.000585	CcSEcCtD
Nilotinib—Infection—Doxorubicin—bone cancer	6.24e-05	0.000583	CcSEcCtD
Nilotinib—Pain—Methotrexate—bone cancer	6.21e-05	0.00058	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—bone cancer	6.19e-05	0.000578	CcSEcCtD
Nilotinib—Shock—Doxorubicin—bone cancer	6.18e-05	0.000578	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—bone cancer	6.16e-05	0.000576	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—bone cancer	6.15e-05	0.000575	CcSEcCtD
Nilotinib—ABCB1—bone marrow—bone cancer	6.15e-05	0.00169	CbGeAlD
Nilotinib—Insomnia—Epirubicin—bone cancer	6.14e-05	0.000574	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—bone cancer	6.13e-05	0.000573	CcSEcCtD
Nilotinib—ABCB1—spinal cord—bone cancer	6.13e-05	0.00169	CbGeAlD
Nilotinib—Skin disorder—Doxorubicin—bone cancer	6.11e-05	0.00057	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—bone cancer	6.1e-05	0.00057	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—bone cancer	6.08e-05	0.000568	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—bone cancer	6.06e-05	0.000566	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—bone cancer	5.99e-05	0.00056	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—bone cancer	5.98e-05	0.000559	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—bone cancer	5.98e-05	0.000559	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—bone cancer	5.94e-05	0.000554	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—bone cancer	5.91e-05	0.000552	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—bone cancer	5.87e-05	0.000549	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—bone cancer	5.87e-05	0.000548	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—bone cancer	5.86e-05	0.000547	CcSEcCtD
Nilotinib—Constipation—Epirubicin—bone cancer	5.81e-05	0.000543	CcSEcCtD
Nilotinib—Pain—Epirubicin—bone cancer	5.81e-05	0.000543	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—bone cancer	5.77e-05	0.000539	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—bone cancer	5.74e-05	0.000536	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—bone cancer	5.74e-05	0.000536	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	5.73e-05	0.000535	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—bone cancer	5.69e-05	0.000531	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—bone cancer	5.64e-05	0.000527	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—bone cancer	5.6e-05	0.000523	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—bone cancer	5.6e-05	0.000523	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—bone cancer	5.56e-05	0.000519	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—bone cancer	5.53e-05	0.000517	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—bone cancer	5.46e-05	0.00051	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—bone cancer	5.43e-05	0.000507	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—bone cancer	5.42e-05	0.000506	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—bone cancer	5.4e-05	0.000504	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—bone cancer	5.38e-05	0.000502	CcSEcCtD
Nilotinib—Pain—Doxorubicin—bone cancer	5.38e-05	0.000502	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—bone cancer	5.37e-05	0.000502	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—bone cancer	5.37e-05	0.000502	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—bone cancer	5.35e-05	0.0005	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—bone cancer	5.21e-05	0.000486	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—bone cancer	5.18e-05	0.000484	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—bone cancer	5.14e-05	0.00048	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—bone cancer	5.14e-05	0.00048	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—bone cancer	5.01e-05	0.000467	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—bone cancer	4.99e-05	0.000466	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—bone cancer	4.97e-05	0.000464	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—bone cancer	4.97e-05	0.000464	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—bone cancer	4.97e-05	0.000464	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—bone cancer	4.87e-05	0.000455	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—bone cancer	4.81e-05	0.000449	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—bone cancer	4.8e-05	0.000448	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—bone cancer	4.65e-05	0.000434	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—bone cancer	4.63e-05	0.000433	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—bone cancer	4.62e-05	0.000431	CcSEcCtD
Nilotinib—Rash—Methotrexate—bone cancer	4.58e-05	0.000428	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—bone cancer	4.57e-05	0.000427	CcSEcCtD
Nilotinib—Headache—Methotrexate—bone cancer	4.55e-05	0.000425	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—bone cancer	4.51e-05	0.000421	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—bone cancer	4.49e-05	0.00042	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—bone cancer	4.45e-05	0.000415	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—bone cancer	4.32e-05	0.000403	CcSEcCtD
Nilotinib—Nausea—Methotrexate—bone cancer	4.31e-05	0.000403	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—bone cancer	4.3e-05	0.000402	CcSEcCtD
Nilotinib—Rash—Epirubicin—bone cancer	4.28e-05	0.0004	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—bone cancer	4.28e-05	0.0004	CcSEcCtD
Nilotinib—Headache—Epirubicin—bone cancer	4.26e-05	0.000398	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—bone cancer	4.16e-05	0.000388	CcSEcCtD
Nilotinib—Nausea—Epirubicin—bone cancer	4.04e-05	0.000377	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—bone cancer	4e-05	0.000373	CcSEcCtD
Nilotinib—Rash—Doxorubicin—bone cancer	3.96e-05	0.00037	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—bone cancer	3.96e-05	0.00037	CcSEcCtD
Nilotinib—Headache—Doxorubicin—bone cancer	3.94e-05	0.000368	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—bone cancer	3.73e-05	0.000349	CcSEcCtD
Nilotinib—LYN—Adaptive Immune System—MDM2—bone cancer	9.35e-06	7.34e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—bone cancer	9.32e-06	7.32e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—PTGS2—bone cancer	9.29e-06	7.29e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—bone cancer	9.28e-06	7.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ATF1—bone cancer	9.27e-06	7.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—MDM2—bone cancer	9.23e-06	7.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SMO—bone cancer	9.12e-06	7.16e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—JUN—bone cancer	9.07e-06	7.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFBR2—bone cancer	9.06e-06	7.12e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL3—bone cancer	9.04e-06	7.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—GNA11—bone cancer	8.99e-06	7.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFBR2—bone cancer	8.98e-06	7.05e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—DHFR—bone cancer	8.94e-06	7.02e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CYP3A4—bone cancer	8.93e-06	7.01e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NDUFA12—bone cancer	8.85e-06	6.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—bone cancer	8.84e-06	6.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—EGFR—bone cancer	8.84e-06	6.94e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—GNA11—bone cancer	8.8e-06	6.91e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	8.8e-06	6.91e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—KIT—bone cancer	8.75e-06	6.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—JUN—bone cancer	8.64e-06	6.79e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1R—bone cancer	8.53e-06	6.7e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—JUN—bone cancer	8.46e-06	6.65e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1R—bone cancer	8.45e-06	6.63e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—JUN—bone cancer	8.42e-06	6.62e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GNA11—bone cancer	8.36e-06	6.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ATF1—bone cancer	8.36e-06	6.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—GNA11—bone cancer	8.34e-06	6.55e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTGS2—bone cancer	8.22e-06	6.46e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—JUN—bone cancer	8.22e-06	6.45e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—JUN—bone cancer	8.22e-06	6.45e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—JUN—bone cancer	8.19e-06	6.43e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ATF1—bone cancer	8.18e-06	6.43e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFBR2—bone cancer	8.17e-06	6.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KIT—bone cancer	8.16e-06	6.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL3—bone cancer	8.15e-06	6.4e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—JUN—bone cancer	8.02e-06	6.3e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFBR2—bone cancer	7.99e-06	6.27e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—MDM2—bone cancer	7.98e-06	6.27e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL3—bone cancer	7.98e-06	6.27e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EGFR—bone cancer	7.97e-06	6.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SMO—bone cancer	7.89e-06	6.19e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—bone cancer	7.88e-06	6.19e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KIT—bone cancer	7.76e-06	6.1e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ATF1—bone cancer	7.76e-06	6.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFBR2—bone cancer	7.74e-06	6.08e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1R—bone cancer	7.69e-06	6.04e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—MDM2—bone cancer	7.66e-06	6.02e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—EGFR—bone cancer	7.65e-06	6.01e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GSTP1—bone cancer	7.64e-06	6e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CYP3A4—bone cancer	7.58e-06	5.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL3—bone cancer	7.56e-06	5.94e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—bone cancer	7.56e-06	5.93e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EGFR—bone cancer	7.54e-06	5.93e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KIT—bone cancer	7.54e-06	5.92e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EGFR—bone cancer	7.53e-06	5.92e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—MDM2—bone cancer	7.53e-06	5.92e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EGFR—bone cancer	7.5e-06	5.89e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—BRAF—bone cancer	7.48e-06	5.88e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KIT—bone cancer	7.38e-06	5.8e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KIT—bone cancer	7.36e-06	5.78e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NT5C3A—bone cancer	7.33e-06	5.76e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—BRAF—bone cancer	7.3e-06	5.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1R—bone cancer	7.28e-06	5.72e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—EGFR—bone cancer	7.24e-06	5.69e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—GNA11—bone cancer	7.21e-06	5.67e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KIT—bone cancer	7.2e-06	5.66e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KIT—bone cancer	7.17e-06	5.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EGFR—bone cancer	7.14e-06	5.61e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—EGFR—bone cancer	7.13e-06	5.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—BRAF—bone cancer	7.09e-06	5.56e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ENO2—bone cancer	7.06e-06	5.55e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFBR2—bone cancer	6.97e-06	5.47e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—JUN—bone cancer	6.94e-06	5.45e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—BRAF—bone cancer	6.94e-06	5.45e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.92e-06	5.43e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MDM2—bone cancer	6.89e-06	5.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KIT—bone cancer	6.83e-06	5.36e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFBR2—bone cancer	6.82e-06	5.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EGFR—bone cancer	6.8e-06	5.34e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—MDM2—bone cancer	6.79e-06	5.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KIT—bone cancer	6.79e-06	5.33e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ATF1—bone cancer	6.71e-06	5.27e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—bone cancer	6.65e-06	5.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—bone cancer	6.64e-06	5.22e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—bone cancer	6.64e-06	5.22e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—bone cancer	6.62e-06	5.2e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—bone cancer	6.58e-06	5.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	6.56e-06	5.15e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—DHFR—bone cancer	6.55e-06	5.15e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—JUN—bone cancer	6.55e-06	5.14e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL3—bone cancer	6.54e-06	5.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	6.53e-06	5.13e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GSTP1—bone cancer	6.48e-06	5.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFBR2—bone cancer	6.47e-06	5.08e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—bone cancer	6.46e-06	5.07e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—bone cancer	6.46e-06	5.07e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—bone cancer	6.44e-06	5.06e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MDM2—bone cancer	6.43e-06	5.05e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1R—bone cancer	6.42e-06	5.04e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—bone cancer	6.39e-06	5.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—BRAF—bone cancer	6.38e-06	5.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—bone cancer	6.31e-06	4.95e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MDM2—bone cancer	6.27e-06	4.93e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—bone cancer	6.21e-06	4.87e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KIT—bone cancer	6.18e-06	4.86e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—bone cancer	6.18e-06	4.85e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KIT—bone cancer	6.13e-06	4.81e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GNA11—bone cancer	6.13e-06	4.81e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MDM2—bone cancer	6.11e-06	4.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1R—bone cancer	6.09e-06	4.78e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—bone cancer	6.05e-06	4.75e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ENO2—bone cancer	5.98e-06	4.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MDM2—bone cancer	5.94e-06	4.66e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—JUN—bone cancer	5.9e-06	4.64e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KIT—bone cancer	5.9e-06	4.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—bone cancer	5.88e-06	4.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—BRAF—bone cancer	5.81e-06	4.57e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MDM2—bone cancer	5.81e-06	4.56e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.81e-06	4.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MDM2—bone cancer	5.79e-06	4.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—bone cancer	5.72e-06	4.5e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MDM2—bone cancer	5.67e-06	4.45e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MDM2—bone cancer	5.65e-06	4.43e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFBR2—bone cancer	5.59e-06	4.39e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—JUN—bone cancer	5.59e-06	4.39e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP3A4—bone cancer	5.55e-06	4.36e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—DHFR—bone cancer	5.55e-06	4.36e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—bone cancer	5.45e-06	4.28e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KIT—bone cancer	5.45e-06	4.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MDM2—bone cancer	5.38e-06	4.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MDM2—bone cancer	5.35e-06	4.2e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—JUN—bone cancer	5.31e-06	4.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KIT—bone cancer	5.28e-06	4.15e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1R—bone cancer	5.26e-06	4.13e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—BRAF—bone cancer	5.24e-06	4.12e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—bone cancer	5.24e-06	4.11e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO2—bone cancer	5.21e-06	4.09e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNA11—bone cancer	5.19e-06	4.07e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—bone cancer	5.17e-06	4.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—bone cancer	5.16e-06	4.05e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—bone cancer	5.15e-06	4.04e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—BRAF—bone cancer	5.12e-06	4.02e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—bone cancer	5.09e-06	4e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—JUN—bone cancer	5.05e-06	3.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—JUN—bone cancer	5.04e-06	3.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—BRAF—bone cancer	4.96e-06	3.9e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—JUN—bone cancer	4.93e-06	3.87e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—bone cancer	4.91e-06	3.86e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO2—bone cancer	4.91e-06	3.86e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—JUN—bone cancer	4.91e-06	3.85e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MDM2—bone cancer	4.87e-06	3.83e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO2—bone cancer	4.87e-06	3.82e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—DHFR—bone cancer	4.83e-06	3.8e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MDM2—bone cancer	4.82e-06	3.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KIT—bone cancer	4.76e-06	3.74e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTP1—bone cancer	4.75e-06	3.73e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—bone cancer	4.71e-06	3.7e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP3A4—bone cancer	4.7e-06	3.69e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.68e-06	3.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—JUN—bone cancer	4.67e-06	3.67e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KIT—bone cancer	4.66e-06	3.66e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MDM2—bone cancer	4.65e-06	3.65e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—bone cancer	4.64e-06	3.65e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—DHFR—bone cancer	4.56e-06	3.58e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNA11—bone cancer	4.52e-06	3.55e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—DHFR—bone cancer	4.52e-06	3.55e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—BRAF—bone cancer	4.47e-06	3.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KIT—bone cancer	4.41e-06	3.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—bone cancer	4.39e-06	3.45e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MDM2—bone cancer	4.39e-06	3.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—BRAF—bone cancer	4.38e-06	3.44e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MDM2—bone cancer	4.29e-06	3.37e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—bone cancer	4.29e-06	3.37e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNA11—bone cancer	4.26e-06	3.34e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—JUN—bone cancer	4.23e-06	3.33e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNA11—bone cancer	4.22e-06	3.32e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—JUN—bone cancer	4.19e-06	3.29e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—bone cancer	4.18e-06	3.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MDM2—bone cancer	4.16e-06	3.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—BRAF—bone cancer	4.15e-06	3.26e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—bone cancer	4.14e-06	3.25e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—bone cancer	4.12e-06	3.24e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP3A4—bone cancer	4.1e-06	3.22e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—bone cancer	4.08e-06	3.2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—bone cancer	4.06e-06	3.19e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—JUN—bone cancer	4.04e-06	3.17e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTP1—bone cancer	4.02e-06	3.16e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—bone cancer	3.97e-06	3.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—bone cancer	3.96e-06	3.11e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—bone cancer	3.96e-06	3.11e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—bone cancer	3.88e-06	3.04e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP3A4—bone cancer	3.86e-06	3.03e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—bone cancer	3.86e-06	3.03e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP3A4—bone cancer	3.83e-06	3.01e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JUN—bone cancer	3.82e-06	3e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—bone cancer	3.82e-06	3e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.81e-06	2.99e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MDM2—bone cancer	3.75e-06	2.94e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—bone cancer	3.71e-06	2.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—bone cancer	3.67e-06	2.89e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MDM2—bone cancer	3.67e-06	2.88e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—bone cancer	3.65e-06	2.87e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JUN—bone cancer	3.61e-06	2.84e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BRAF—bone cancer	3.59e-06	2.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—bone cancer	3.52e-06	2.76e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—bone cancer	3.51e-06	2.75e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—bone cancer	3.5e-06	2.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MDM2—bone cancer	3.48e-06	2.73e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—bone cancer	3.36e-06	2.64e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—bone cancer	3.33e-06	2.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—bone cancer	3.33e-06	2.61e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—bone cancer	3.3e-06	2.59e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—bone cancer	3.3e-06	2.59e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—bone cancer	3.27e-06	2.57e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JUN—bone cancer	3.26e-06	2.56e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO2—bone cancer	3.21e-06	2.52e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—bone cancer	3.19e-06	2.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—bone cancer	3.18e-06	2.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—bone cancer	3.17e-06	2.49e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—bone cancer	3.1e-06	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—bone cancer	3.02e-06	2.37e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—bone cancer	3.01e-06	2.36e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—bone cancer	3e-06	2.36e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DHFR—bone cancer	2.98e-06	2.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—bone cancer	2.94e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—bone cancer	2.93e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—bone cancer	2.84e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—bone cancer	2.79e-06	2.19e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNA11—bone cancer	2.78e-06	2.19e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—bone cancer	2.77e-06	2.17e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—bone cancer	2.61e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—bone cancer	2.56e-06	2.01e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—bone cancer	2.54e-06	2e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—bone cancer	2.52e-06	1.98e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—bone cancer	2.51e-06	1.97e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—bone cancer	2.46e-06	1.93e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—bone cancer	2.39e-06	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—bone cancer	2.38e-06	1.87e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—bone cancer	2.16e-06	1.7e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—bone cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—bone cancer	2.1e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—bone cancer	2.08e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—bone cancer	2.05e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—bone cancer	1.99e-06	1.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—bone cancer	1.81e-06	1.43e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—bone cancer	1.72e-06	1.35e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—bone cancer	1.71e-06	1.34e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—bone cancer	1.7e-06	1.33e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—bone cancer	1.12e-06	8.78e-06	CbGpPWpGaD
